Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

103.17
+1.391.37%
Pre-market: 105.322.15+2.08%04:00 EDT
Volume:94.74K
Turnover:9.75M
Market Cap:4.35B
PE:-100.33
High:103.36
Open:101.87
Low:101.75
Close:101.78
52wk High:107.69
52wk Low:90.24
Shares:42.15M
Float Shares:42.15M
Volume Ratio:0.59
T/O Rate:0.22%
Dividend:1.44
Dividend Rate:1.40%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.12
PE(LYR):-100.33

Loading ...

UnitedHealth Price Target Cut to $402.00/Share from $430.00 by TD Cowen

Dow Jones
·
Oct 10

Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says

MT Newswires Live
·
Oct 09

UBS Lifts AbbVie Target as Focus Expands Beyond Immunology Drugs

Reuters
·
Oct 09

Millions of Americans Will Have Fewer Options During Medicare Open Enrollment This Year

Dow Jones
·
Oct 09

1 Drugs Could Ease Back and Knee Pain, but Doctors Say There are Risks for Older Adults

Dow Jones
·
Oct 09

Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

TIPRANKS
·
Oct 09

BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating

MT Newswires Live
·
Oct 09

UnitedHealth, Amazon.Com Inc. Share Gains Contribute to Dow's 138-Point Jump

Dow Jones
·
Oct 09

Abbvie Inc. : UBS Raises Target Price to $275 from $260

THOMSON REUTERS
·
Oct 09

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Oct 09

Merck & Company (MRK) Receives a Buy from UBS

TIPRANKS
·
Oct 09

UnitedHealth price target lowered to $402 from $430 at TD Cowen

TIPRANKS
·
Oct 09

U.S. Stocks on the MOVE-SpaceX, Humana, Delta Air Lines

Reuters
·
Oct 09

Piper Sandler recommends buying UnitedHealth on 2027 Star Ratings release

TIPRANKS
·
Oct 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 09

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
Oct 09

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
Oct 09

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
Oct 09

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
Oct 09

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
Oct 09